tetano
Editor, Senior Moderator
Am J Ophthalmol
. 2024 Feb 8:S0002-9394(24)00041-2.
doi: 10.1016/j.ajo.2024.01.038. Online ahead of print. Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study
Hae Rang Kim[SUP] 1 [/SUP], Sunyeup Kim[SUP] 2 [/SUP], Myung Soo Chang[SUP] 3 [/SUP], Christopher Seungkyu Lee[SUP] 3 [/SUP], Suk Ho Byeon[SUP] 3 [/SUP], Sung Soo Kim[SUP] 3 [/SUP], Seung Won Lee[SUP] 4 [/SUP], Yong Joon Kim[SUP] 5 [/SUP]
Affiliations
Purpose: To investigate the risk of noninfectious uveitis following the first dose of coronavirus disease 2019 (COVID-19) vaccination based on the uveitis history.
Design: Retrospective matched cohort and crossover case series study METHODS: A random sample of 7,917,457 individuals who received COVID-19 vaccine between January 2021 and March 2022 in Korea, and had no recorded history of COVID-19 were categorized into the control and uveitis groups based on their uveitis history. After performing 3:1 propensity score matching, we assessed the cumulative incidence and risk of noninfectious uveitis in the 180 days after COVID-19 vaccination. Additionally, we performed a crossover case series analysis to compare the pre- and post-vaccination incidence rate ratios (IRRs) of uveitis in individuals with and without a history of uveitis.
Results: In the matched cohort analysis, uveitis group had a significantly higher cumulative incidence of uveitis (15.4%) than control group (0.10%). The uveitis group exhibited increased risks of all uveitis types, anterior, and non-anterior uveitis in the first 60 days (hazard ratio
: 169, 158, and 253, respectively) and in days 61-180 (HR: 166, 164, and 143, respectively) after vaccination. In the crossover case series analysis, uveitis occurred with relatively equal frequency in 20 day intervals during the 180 days before and after vaccination, regardless of uveitis history. For uveitis group, the adjusted IRRs for early and late post-vaccination events were 0.92 (95% CI, 0.88-0.96) and 0.83 (95% CI, 0.80-0.85), respectively.
Conclusions: COVID-19 vaccination did not increase the risk of uveitis, regardless of uveitis history.
Keywords: Coronavirus Disease 2019 vaccination; noninfectious uveitis; recurrent uveitis.
. 2024 Feb 8:S0002-9394(24)00041-2.
doi: 10.1016/j.ajo.2024.01.038. Online ahead of print. Uveitis Risk After the First Dose of COVID-19 Vaccination Based on Uveitis History: Matched Cohort and Crossover Case Series Study
Hae Rang Kim[SUP] 1 [/SUP], Sunyeup Kim[SUP] 2 [/SUP], Myung Soo Chang[SUP] 3 [/SUP], Christopher Seungkyu Lee[SUP] 3 [/SUP], Suk Ho Byeon[SUP] 3 [/SUP], Sung Soo Kim[SUP] 3 [/SUP], Seung Won Lee[SUP] 4 [/SUP], Yong Joon Kim[SUP] 5 [/SUP]
Affiliations
- PMID: 38341167
- DOI: 10.1016/j.ajo.2024.01.038
Purpose: To investigate the risk of noninfectious uveitis following the first dose of coronavirus disease 2019 (COVID-19) vaccination based on the uveitis history.
Design: Retrospective matched cohort and crossover case series study METHODS: A random sample of 7,917,457 individuals who received COVID-19 vaccine between January 2021 and March 2022 in Korea, and had no recorded history of COVID-19 were categorized into the control and uveitis groups based on their uveitis history. After performing 3:1 propensity score matching, we assessed the cumulative incidence and risk of noninfectious uveitis in the 180 days after COVID-19 vaccination. Additionally, we performed a crossover case series analysis to compare the pre- and post-vaccination incidence rate ratios (IRRs) of uveitis in individuals with and without a history of uveitis.
Results: In the matched cohort analysis, uveitis group had a significantly higher cumulative incidence of uveitis (15.4%) than control group (0.10%). The uveitis group exhibited increased risks of all uveitis types, anterior, and non-anterior uveitis in the first 60 days (hazard ratio
: 169, 158, and 253, respectively) and in days 61-180 (HR: 166, 164, and 143, respectively) after vaccination. In the crossover case series analysis, uveitis occurred with relatively equal frequency in 20 day intervals during the 180 days before and after vaccination, regardless of uveitis history. For uveitis group, the adjusted IRRs for early and late post-vaccination events were 0.92 (95% CI, 0.88-0.96) and 0.83 (95% CI, 0.80-0.85), respectively.
Conclusions: COVID-19 vaccination did not increase the risk of uveitis, regardless of uveitis history.
Keywords: Coronavirus Disease 2019 vaccination; noninfectious uveitis; recurrent uveitis.